Top Markets
#1 Seeker Seeker +136.83%
#2 AI XOVIA AI XOVIA +101.43%
#3 Helium Helium +75.99%
#4 MowCat MowCat +69.58%
#5 Pons Pons +42.35%
#6 UnifAI Network UnifAI Network +35.30%
#7 Zora Zora +30.19%
#8 Bounce Bounce +23.42%
#9 Zylo Ecosystem Zylo Ecosystem +20.57%
#10 TENDIES TENDIES +17.54%
Coin of the day
Seeker Seeker
Settings
Language
ENGLISH
Currency
USD
Theme
AgomAb Therapeutics N.V. American Depositary Shares AgomAb Therapeutics N.V. American Depositary Shares

AgomAb Therapeutics N.V. American Depositary Shares

AGMB
Rank in Stocks #11835
AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company... AgomAb Therapeutics N.V. is a clinical-stage biopharmaceutical company dedicated to developing novel, disease-modifying therapies. Its primary focus lies in immunology and inflammatory ailments, particularly chronic fibrotic conditions where significant unmet medical needs persist. Its innovative pipeline features several promising candidates, including Ontunisertib (AGMB-129), an orally administered, gastrointestinal-restricted small molecule inhibitor targeting ALK5 or TGFßR1, designed to treat Fibrostenosing Crohn's disease and presently undergoing Phase 2a clinical trials. Also in development is AGMB-447, an inhaled small molecule that similarly inhibits ALK5 or TGFßR1, intended for idiopathic pulmonary fibrosis and currently in Phase 1 clinical studies. Furthermore, the company is advancing AGMB-101, a monoclonal antibody designed to mimic HGF. This agent exerts its effects through the agonism or stimulation of the MET receptor, having demonstrated both antifibrotic and regenerative capabilities in preclinical models. Established in 2017, AgomAb Therapeutics maintains its headquarters in Antwerp, Belgium.
Share Price
$13.26
Last synced: 2026-08-28
Market Cap
$653.15M
Change (1 day)
-4.17%
Change (1 year)
-
Country
BE
Trade AgomAb Therapeutics N.V. American Depositary Shares (AGMB)

Category

Healthcare
P/E ratio for AgomAb Therapeutics N.V. American Depositary Shares (AGMB)
P/E ratio as of 2026 TTM: 0
According to AgomAb Therapeutics N.V. American Depositary Shares latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for AgomAb Therapeutics N.V. American Depositary Shares from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.